Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
The global Anti-epileptic Drugs for Pediatrics market was valued at US$ 1102 million in 2023 and is anticipated to reach US$ 1863 million by 2030, witnessing a CAGR of 7.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-epileptic Drugs for Pediatrics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-epileptic Drugs for Pediatrics.
Report Scope
The Anti-epileptic Drugs for Pediatrics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-epileptic Drugs for Pediatrics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-epileptic Drugs for Pediatrics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Bausch Health Companies Inc.
Johnson & Johnson Service
Teva Pharmaceutical Industries Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Segment by Type
1st Generation
2nd Generation
3rd Generation
Segment by Application
Hospitals
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-epileptic Drugs for Pediatrics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-epileptic Drugs for Pediatrics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Anti-epileptic Drugs for Pediatrics 麻豆原创 Overview
1.1 Product Overview and Scope of Anti-epileptic Drugs for Pediatrics
1.2 Anti-epileptic Drugs for Pediatrics Segment by Type
1.2.1 Global Anti-epileptic Drugs for Pediatrics 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 1st Generation
1.2.3 2nd Generation
1.2.4 3rd Generation
1.3 Anti-epileptic Drugs for Pediatrics Segment by Application
1.3.1 Global Anti-epileptic Drugs for Pediatrics 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Anti-epileptic Drugs for Pediatrics 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2019-2030
1.4.2 Global Anti-epileptic Drugs for Pediatrics Sales 2019-2030
1.4.3 Global Anti-epileptic Drugs for Pediatrics 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-epileptic Drugs for Pediatrics 麻豆原创 Competition by Manufacturers
2.1 Global Anti-epileptic Drugs for Pediatrics Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Anti-epileptic Drugs for Pediatrics Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Anti-epileptic Drugs for Pediatrics Average Price by Manufacturers (2019-2024)
2.4 Global Anti-epileptic Drugs for Pediatrics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-epileptic Drugs for Pediatrics, Product Type & Application
2.7 Anti-epileptic Drugs for Pediatrics 麻豆原创 Competitive Situation and Trends
2.7.1 Anti-epileptic Drugs for Pediatrics 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-epileptic Drugs for Pediatrics Players 麻豆原创 Share by Revenue
2.7.3 Global Anti-epileptic Drugs for Pediatrics 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-epileptic Drugs for Pediatrics Retrospective 麻豆原创 Scenario by Region
3.1 Global Anti-epileptic Drugs for Pediatrics 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-epileptic Drugs for Pediatrics Global Anti-epileptic Drugs for Pediatrics Sales by Region: 2019-2030
3.2.1 Global Anti-epileptic Drugs for Pediatrics Sales by Region: 2019-2024
3.2.2 Global Anti-epileptic Drugs for Pediatrics Sales by Region: 2025-2030
3.3 Global Anti-epileptic Drugs for Pediatrics Global Anti-epileptic Drugs for Pediatrics Revenue by Region: 2019-2030
3.3.1 Global Anti-epileptic Drugs for Pediatrics Revenue by Region: 2019-2024
3.3.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Region: 2025-2030
3.4 North America Anti-epileptic Drugs for Pediatrics 麻豆原创 Facts & Figures by Country
3.4.1 North America Anti-epileptic Drugs for Pediatrics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-epileptic Drugs for Pediatrics Sales by Country (2019-2030)
3.4.3 North America Anti-epileptic Drugs for Pediatrics Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anti-epileptic Drugs for Pediatrics 麻豆原创 Facts & Figures by Country
3.5.1 Europe Anti-epileptic Drugs for Pediatrics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-epileptic Drugs for Pediatrics Sales by Country (2019-2030)
3.5.3 Europe Anti-epileptic Drugs for Pediatrics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-epileptic Drugs for Pediatrics 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Anti-epileptic Drugs for Pediatrics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Anti-epileptic Drugs for Pediatrics 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Anti-epileptic Drugs for Pediatrics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country (2019-2030)
3.7.3 Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-epileptic Drugs for Pediatrics 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2019-2030)
4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2019-2024)
4.1.2 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2025-2030)
4.1.3 Global Anti-epileptic Drugs for Pediatrics Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2019-2030)
4.2.1 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2019-2024)
4.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2025-2030)
4.2.3 Global Anti-epileptic Drugs for Pediatrics Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Anti-epileptic Drugs for Pediatrics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2019-2030)
5.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2019-2024)
5.1.2 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2025-2030)
5.1.3 Global Anti-epileptic Drugs for Pediatrics Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2019-2030)
5.2.1 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2019-2024)
5.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2025-2030)
5.2.3 Global Anti-epileptic Drugs for Pediatrics Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Anti-epileptic Drugs for Pediatrics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Mylan N.V
6.1.1 Mylan N.V Corporation Information
6.1.2 Mylan N.V Description and Business Overview
6.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Product Portfolio
6.1.5 Mylan N.V Recent Developments/Updates
6.2 Cephalon, Inc
6.2.1 Cephalon, Inc Corporation Information
6.2.2 Cephalon, Inc Description and Business Overview
6.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio
6.2.5 Cephalon, Inc Recent Developments/Updates
6.3 GlaxoSmithKline plc
6.3.1 GlaxoSmithKline plc Corporation Information
6.3.2 GlaxoSmithKline plc Description and Business Overview
6.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product Portfolio
6.3.5 GlaxoSmithKline plc Recent Developments/Updates
6.4 Janssen Pharmaceuticals
6.4.1 Janssen Pharmaceuticals Corporation Information
6.4.2 Janssen Pharmaceuticals Description and Business Overview
6.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Portfolio
6.4.5 Janssen Pharmaceuticals Recent Developments/Updates
6.5 Novartis AG
6.5.1 Novartis AG Corporation Information
6.5.2 Novartis AG Description and Business Overview
6.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Product Portfolio
6.5.5 Novartis AG Recent Developments/Updates
6.6 Pfizer, Inc
6.6.1 Pfizer, Inc Corporation Information
6.6.2 Pfizer, Inc Description and Business Overview
6.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio
6.6.5 Pfizer, Inc Recent Developments/Updates
6.7 Sanofi S.A
6.6.1 Sanofi S.A Corporation Information
6.6.2 Sanofi S.A Description and Business Overview
6.6.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Product Portfolio
6.7.5 Sanofi S.A Recent Developments/Updates
6.8 UCB Pharma Limited
6.8.1 UCB Pharma Limited Corporation Information
6.8.2 UCB Pharma Limited Description and Business Overview
6.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product Portfolio
6.8.5 UCB Pharma Limited Recent Developments/Updates
6.9 Sunovion Pharmaceuticals Limited
6.9.1 Sunovion Pharmaceuticals Limited Corporation Information
6.9.2 Sunovion Pharmaceuticals Limited Description and Business Overview
6.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product Portfolio
6.9.5 Sunovion Pharmaceuticals Limited Recent Developments/Updates
6.10 Valeant Pharmaceuticals International, Inc
6.10.1 Valeant Pharmaceuticals International, Inc Corporation Information
6.10.2 Valeant Pharmaceuticals International, Inc Description and Business Overview
6.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Product Portfolio
6.10.5 Valeant Pharmaceuticals International, Inc Recent Developments/Updates
6.11 Zogenix
6.11.1 Zogenix Corporation Information
6.11.2 Zogenix Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.11.3 Zogenix Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Zogenix Anti-epileptic Drugs for Pediatrics Product Portfolio
6.11.5 Zogenix Recent Developments/Updates
6.12 GW Pharmaceuticals
6.12.1 GW Pharmaceuticals Corporation Information
6.12.2 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.12.3 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Portfolio
6.12.5 GW Pharmaceuticals Recent Developments/Updates
6.13 Insys
6.13.1 Insys Corporation Information
6.13.2 Insys Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.13.3 Insys Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Insys Anti-epileptic Drugs for Pediatrics Product Portfolio
6.13.5 Insys Recent Developments/Updates
6.14 Zynerba
6.14.1 Zynerba Corporation Information
6.14.2 Zynerba Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.14.3 Zynerba Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Zynerba Anti-epileptic Drugs for Pediatrics Product Portfolio
6.14.5 Zynerba Recent Developments/Updates
6.15 Bausch Health Companies Inc.
6.15.1 Bausch Health Companies Inc. Corporation Information
6.15.2 Bausch Health Companies Inc. Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.15.3 Bausch Health Companies Inc. Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Bausch Health Companies Inc. Anti-epileptic Drugs for Pediatrics Product Portfolio
6.15.5 Bausch Health Companies Inc. Recent Developments/Updates
6.16 Johnson & Johnson Service
6.16.1 Johnson & Johnson Service Corporation Information
6.16.2 Johnson & Johnson Service Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.16.3 Johnson & Johnson Service Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Johnson & Johnson Service Anti-epileptic Drugs for Pediatrics Product Portfolio
6.16.5 Johnson & Johnson Service Recent Developments/Updates
6.17 Teva Pharmaceutical Industries Ltd.
6.17.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.17.2 Teva Pharmaceutical Industries Ltd. Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.17.3 Teva Pharmaceutical Industries Ltd. Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Teva Pharmaceutical Industries Ltd. Anti-epileptic Drugs for Pediatrics Product Portfolio
6.17.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.18 Sumitomo Dainippon Pharma Co., Ltd.
6.18.1 Sumitomo Dainippon Pharma Co., Ltd. Corporation Information
6.18.2 Sumitomo Dainippon Pharma Co., Ltd. Anti-epileptic Drugs for Pediatrics Description and Business Overview
6.18.3 Sumitomo Dainippon Pharma Co., Ltd. Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Sumitomo Dainippon Pharma Co., Ltd. Anti-epileptic Drugs for Pediatrics Product Portfolio
6.18.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-epileptic Drugs for Pediatrics Industry Chain Analysis
7.2 Anti-epileptic Drugs for Pediatrics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-epileptic Drugs for Pediatrics Production Mode & Process
7.4 Anti-epileptic Drugs for Pediatrics Sales and 麻豆原创ing
7.4.1 Anti-epileptic Drugs for Pediatrics Sales Channels
7.4.2 Anti-epileptic Drugs for Pediatrics Distributors
7.5 Anti-epileptic Drugs for Pediatrics Customers
8 Anti-epileptic Drugs for Pediatrics 麻豆原创 Dynamics
8.1 Anti-epileptic Drugs for Pediatrics Industry Trends
8.2 Anti-epileptic Drugs for Pediatrics 麻豆原创 Drivers
8.3 Anti-epileptic Drugs for Pediatrics 麻豆原创 Challenges
8.4 Anti-epileptic Drugs for Pediatrics 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Bausch Health Companies Inc.
Johnson & Johnson Service
Teva Pharmaceutical Industries Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
听
听
*If Applicable.